Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine

Athens 115 22

0 studies enrolling now · 2 studies all time

What they study most

Advanced BRAFV600 Wild-type Melanoma, Triple-Negative Breast Cancer

Studies at this site

• A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) — Completed
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma — Stopped early